• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthMichael Bloomberg

Michael Bloomberg’s radical plan to cut prescription drug costs

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
January 28, 2020, 6:44 PM ET

In recent years, the rising cost of prescription drugs has been top of mind for consumers and politicians alike. Now Democratic presidential candidate Michael Bloomberg is in on the discussion, citing price increases at a rate five times higher than inflation for 3,400 drugs during the first six months of 2019.

Earlier this week, Bloomberg suggested proposed upending the number of patents a therapy can benefit from as a way to slash the cost of prescription drugs. In fact, Bloomberg’s proposal would restrict new brand name medications to just one patent.

That would limit companies to one 20-year patent period for new branded pharmaceuticals. Right now they can also extend their market dominance by establishing follow-on patents, a process dubbed “evergreening.” Bloomberg’s proposal would take a buzzsaw to that process.

Pharmaceutical companies regularly use patents—including “patent thickets”—to protect their cash cows. For instance, companies commonly seek new patents to iron out wrinkles in a manufacturing procedure for a drug, or tweaks to dosages and delivery mechanisms for a treatment. Along the way? The evergreening thwarts competition from cheaper generic rivals .

There could, however, be other ways to achieve the same goal. For instance, a drug’s initial patent might dictate when generic competitors are allowed on the market (without discounting follow-on patents for ensuing innovations).

And Bloomberg isn’t the only Democratic candidate challenging the drug industry. Sens. Elizabeth Warren and Bernie Sanders, as well as other presidential hopefuls, have endorsed a range of drug pricing reforms spanning the gamut from direct Medicare price negotiations to upending the current biopharma IP system.

A recent Morning Consult poll has Bloomberg surging to 12% support nationally. He’s still a long-shot for the Democratic nomination—but proposals like this from a billionaire could shape the conversation udring the primary stretch.

More must-read stories from Fortune:

—10 stocks that are poised for a stellar 2020
—Will retiring baby boomers crash the stock market?
—Millions have been purged from voter rolls—and may not even realize it
—Inside New York City’s Chinese restaurant crisis
—All of your questions on filing taxes in 2020, answered

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon

Latest in Health

HealthAffordable Care Act (ACA)
A Wisconsin couple was paying $2 a month for an ACA health plan. But as subsidies expire, it’s soaring to $1,600, forcing them to downgrade
By Ali Swenson and The Associated PressDecember 13, 2025
11 hours ago
Julian Braithwaite is the Director General of the International Alliance for Responsible Drinking
CommentaryProductivity
Gen Z is drinking 20% less than Millennials. Productivity is rising. Coincidence? Not quite
By Julian BraithwaiteDecember 13, 2025
12 hours ago
Nicholas Thompson
C-SuiteBook Excerpt
I took over one of the most prestigious media firms while training for an ultramarathon. Here’s what I learned becoming CEO of The Atlantic
By Nicholas ThompsonDecember 13, 2025
14 hours ago
Healthmeal delivery
Factor Meals Review 2025: Tester Approved
By Christina SnyderDecember 12, 2025
1 day ago
Donald Trump
HealthHealth Insurance
‘Tragedy in the making’: Top healthcare exec on why insurance will spike to subsidize a tax cut to millionaires and billionaires
By Nick LichtenbergDecember 12, 2025
1 day ago
HelloFresh meal delivery service.
Healthmeal delivery
HelloFresh Review : We Tasted Everything so You Don’t Have To
By Christina SnyderDecember 12, 2025
1 day ago

Most Popular

placeholder alt text
Success
Apple cofounder Ronald Wayne sold his 10% stake for $800 in 1976—today it’d be worth up to $400 billion
By Preston ForeDecember 12, 2025
1 day ago
placeholder alt text
Economy
Tariffs are taxes and they were used to finance the federal government until the 1913 income tax. A top economist breaks it down
By Kent JonesDecember 12, 2025
2 days ago
placeholder alt text
Success
40% of Stanford undergrads receive disability accommodations—but it’s become a college-wide phenomenon as Gen Z try to succeed in the current climate
By Preston ForeDecember 12, 2025
1 day ago
placeholder alt text
Economy
The Fed just ‘Trump-proofed’ itself with a unanimous move to preempt a potential leadership shake-up
By Jason MaDecember 12, 2025
1 day ago
placeholder alt text
Economy
For the first time since Trump’s tariff rollout, import tax revenue has fallen, threatening his lofty plans to slash the $38 trillion national debt
By Sasha RogelbergDecember 12, 2025
1 day ago
placeholder alt text
Success
Apple CEO Tim Cook out-earns the average American’s salary in just 7 hours—to put that into context, he could buy a new $439,000 home in just 2 days
By Emma BurleighDecember 12, 2025
1 day ago
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.